Refractory Sarcoidosis Responding to Infliximab

Scott D. Roberts, David S. Wilkes, Richard A. Burgett, Kenneth S. Knox

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Despite aggressive treatment with conventional therapy, sarcoidosis may be progressive and debilitating. Tumor necrosis factor (TNF)-α is critical in the genesis and maintenance of granulomatous inflammation. Agents developed to inhibit TNF-α have been approved to treat rheumatoid arthritis and inflammatory bowel disease with unprecedented success. As such, physicians are increasingly using these agents to treat patients with other inflammatory diseases, including sarcoidosis. We report a case of refractory sarcoidosis, involving the lung, eyes, skin, and heart, which flared despite aggressive therapy. Oculocutaneous sarcoid dramatically improved after treatment with the anti-TNF antibody infliximab.

Original languageEnglish
Pages (from-to)2028-2031
Number of pages4
JournalChest
Volume124
Issue number5
DOIs
StatePublished - Nov 2003

Fingerprint

Sarcoidosis
Tumor Necrosis Factor-alpha
Therapeutics
Inflammatory Bowel Diseases
Rheumatoid Arthritis
Maintenance
Inflammation
Physicians
Lung
Skin
Infliximab
Antibodies

Keywords

  • Cutaneous
  • Infliximab
  • Ocular
  • Sarcoidosis
  • Tumor necrosis factor-α
  • Uveitis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Roberts, S. D., Wilkes, D. S., Burgett, R. A., & Knox, K. S. (2003). Refractory Sarcoidosis Responding to Infliximab. Chest, 124(5), 2028-2031. https://doi.org/10.1378/chest.124.5.2028

Refractory Sarcoidosis Responding to Infliximab. / Roberts, Scott D.; Wilkes, David S.; Burgett, Richard A.; Knox, Kenneth S.

In: Chest, Vol. 124, No. 5, 11.2003, p. 2028-2031.

Research output: Contribution to journalArticle

Roberts, SD, Wilkes, DS, Burgett, RA & Knox, KS 2003, 'Refractory Sarcoidosis Responding to Infliximab', Chest, vol. 124, no. 5, pp. 2028-2031. https://doi.org/10.1378/chest.124.5.2028
Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory Sarcoidosis Responding to Infliximab. Chest. 2003 Nov;124(5):2028-2031. https://doi.org/10.1378/chest.124.5.2028
Roberts, Scott D. ; Wilkes, David S. ; Burgett, Richard A. ; Knox, Kenneth S. / Refractory Sarcoidosis Responding to Infliximab. In: Chest. 2003 ; Vol. 124, No. 5. pp. 2028-2031.
@article{952b4292f6154be5aad6fb8f22101778,
title = "Refractory Sarcoidosis Responding to Infliximab",
abstract = "Despite aggressive treatment with conventional therapy, sarcoidosis may be progressive and debilitating. Tumor necrosis factor (TNF)-α is critical in the genesis and maintenance of granulomatous inflammation. Agents developed to inhibit TNF-α have been approved to treat rheumatoid arthritis and inflammatory bowel disease with unprecedented success. As such, physicians are increasingly using these agents to treat patients with other inflammatory diseases, including sarcoidosis. We report a case of refractory sarcoidosis, involving the lung, eyes, skin, and heart, which flared despite aggressive therapy. Oculocutaneous sarcoid dramatically improved after treatment with the anti-TNF antibody infliximab.",
keywords = "Cutaneous, Infliximab, Ocular, Sarcoidosis, Tumor necrosis factor-α, Uveitis",
author = "Roberts, {Scott D.} and Wilkes, {David S.} and Burgett, {Richard A.} and Knox, {Kenneth S.}",
year = "2003",
month = "11",
doi = "10.1378/chest.124.5.2028",
language = "English",
volume = "124",
pages = "2028--2031",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Refractory Sarcoidosis Responding to Infliximab

AU - Roberts, Scott D.

AU - Wilkes, David S.

AU - Burgett, Richard A.

AU - Knox, Kenneth S.

PY - 2003/11

Y1 - 2003/11

N2 - Despite aggressive treatment with conventional therapy, sarcoidosis may be progressive and debilitating. Tumor necrosis factor (TNF)-α is critical in the genesis and maintenance of granulomatous inflammation. Agents developed to inhibit TNF-α have been approved to treat rheumatoid arthritis and inflammatory bowel disease with unprecedented success. As such, physicians are increasingly using these agents to treat patients with other inflammatory diseases, including sarcoidosis. We report a case of refractory sarcoidosis, involving the lung, eyes, skin, and heart, which flared despite aggressive therapy. Oculocutaneous sarcoid dramatically improved after treatment with the anti-TNF antibody infliximab.

AB - Despite aggressive treatment with conventional therapy, sarcoidosis may be progressive and debilitating. Tumor necrosis factor (TNF)-α is critical in the genesis and maintenance of granulomatous inflammation. Agents developed to inhibit TNF-α have been approved to treat rheumatoid arthritis and inflammatory bowel disease with unprecedented success. As such, physicians are increasingly using these agents to treat patients with other inflammatory diseases, including sarcoidosis. We report a case of refractory sarcoidosis, involving the lung, eyes, skin, and heart, which flared despite aggressive therapy. Oculocutaneous sarcoid dramatically improved after treatment with the anti-TNF antibody infliximab.

KW - Cutaneous

KW - Infliximab

KW - Ocular

KW - Sarcoidosis

KW - Tumor necrosis factor-α

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=0242721169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242721169&partnerID=8YFLogxK

U2 - 10.1378/chest.124.5.2028

DO - 10.1378/chest.124.5.2028

M3 - Article

C2 - 14605086

AN - SCOPUS:0242721169

VL - 124

SP - 2028

EP - 2031

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -